Imatinib Grindeks (Imatinib)

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is indicated for the following conditions:

• Chronic myeloid leukemia (CML): improves disease control and prolongs survival in patients with BCR‑ABL positive disease.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission and long‑term survival when combined with chemotherapy.
• Gastrointestinal stromal tumor (GIST): reduces tumor growth and delays progression in patients with KIT or PDGFR mutations.

• Imatinib selectively inhibits the intracellular tyrosine‑kinase activity of BCR‑ABL, c‑KIT, and PDGFR. By binding to the ATP‑binding pocket of these enzymes, it blocks downstream signaling that drives cell proliferation, survival, and angiogenesis, leading to apoptosis of malignant cells that depend on these pathways.

Imatinib may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

• Nausea
• Edema (especially peripheral)
• Muscle cramps or pain
• Fatigue
• Diarrhea
• Rash or skin irritation

Serious or Rare Side Effects

• Hepatotoxicity (elevated liver enzymes, hepatitis)
• Severe neutropenia or thrombocytopenia
• Cardiac failure or reduced left‑ventricular function
• Pulmonary arterial hypertension
• Anaphylactic or severe allergic reactions
• Tumor lysis syndrome

Before initiating therapy, clinicians should evaluate baseline organ function and monitor patients regularly.

• Monitor blood counts: perform complete blood count at baseline and periodically during treatment.
• Assess liver function: check hepatic enzymes before start and during therapy.
• Evaluate cardiac status: perform ECG or echocardiogram in patients with pre‑existing heart disease.
• Pregnancy risk: avoid use in pregnancy unless benefits outweigh risks; advise effective contraception.
• Dose adjustment: consider reduced dose in moderate hepatic impairment.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib plasma levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase anticoagulant effect; monitor INR.
• Diuretics (e.g., furosemide): may enhance risk of electrolyte disturbances.
• QT‑prolonging agents (e.g., sotalol): monitor cardiac rhythm and QT interval.